SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1
Document Type: EX-1.1
Date Filed: 2025-08-15
Accession Number: 0001213900-25-077458
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025077458/ea024071103ex1-1_synergy.htm

Chunk 15 of 19
Word Count: 1498
Character Count: 9508

Document Content:

forth in the “Underwriting” section of the Registration Statement, the Time of Sale Disclosure Package, and the Final Prospectus only insofar as such statements relate to the amount of selling concession and re-allowance, if any, or to over-allotment, stabilization and related activities that may be undertaken by the Underwriters. 8. Representations and Agreements to Survive Delivery. All representations, warranties, and agreements of the Company contained herein or in certificates delivered pursuant hereto, including, but not limited to, the agreements of the several Underwriters and the Company contained in Section 5(a)(viii) and Section 7 hereof, shall remain operative and in full force and effect regardless of any investigation made by or on behalf of the Underwriters or any controlling person thereof, or the Company, any of its officers, directors, or controlling persons, and shall survive delivery of, and payment for, the Shares and the Representative Warrants. 9. Termination of this Agreement.

(a) The Representative shall
have the right to terminate this Agreement by giving notice to the Company as hereinafter specified at any time at or prior to the Closing
Date if: (i) trading generally shall have been suspended or materially limited on or by any of the New York Stock Exchange, NYSE American
or the Nasdaq Stock Market; (ii) trading of any securities issued or guaranteed by the Company shall have been suspended or materially
limited on any exchange or in any over-the-counter market; (iii) a general moratorium on commercial banking activities shall have
been declared by any authorities of the United States of America or of the State of New York; (iv) there shall have occurred any
outbreak or escalation of national or international hostilities, or any crisis or calamity, or any change in national or international
financial markets, or any change or development in national or international political, financial or economic conditions that, in each
case, in the judgment of the Representative, is material and adverse and makes it impracticable or inadvisable to proceed with the Offering,
or the sale or delivery of the Shares on the Closing Date on the terms and in the manner contemplated by this Agreement, the Registration
Statement, the Time of Sale Disclosure Package or the Final Prospectus; or (v) in the reasonable judgment of the Representative,
there has been, since the time of execution of this Agreement, or since the respective dates as of which information is given in the Registration
Statement, the Time of Sale Disclosure Package or the Final Prospectus, any material adverse effect on the assets, properties, condition,
financial or otherwise, or in the results of operations, business affairs or business prospects of the Company, whether or not arising
in the ordinary course of business Any such termination shall be without liability of any party to any other party except that the provisions
of Section 5(a)(viii) and Section 7 hereof shall at all times be effective and shall survive such termination.

(b) If the Representative elects
to terminate this Agreement as provided in this Section, the Company shall be notified promptly by the Representative by telephone, confirmed
by letter.

10. Notices.
Except as otherwise provided herein, all communications hereunder shall be in writing shall be mailed, delivered or sent via electronic
mail to the parties as follows:

if to the Representative:

Bancroft Capital, LLC

501 Office Center Drive, Suite

Fort Washington, PA 19034

Attention: Jason Diamond,
Head of Investment Banking

E-Mail: jdiamond@bancroft4vets.com

with a copy (which shall not constitute
notice) to:

Lucosky Brookman LLP

101 Wood Avenue South, 5th Floor

Iselin, NJ 08830

Attention: Lawrence Metelitsa, Esq.

E-Mail: lmetelitsa@lucbro.com

if to the Company:

Synergy CHC Corp.

865 Spring Street

Westbrooke, ME 04092

Attention: Jack Ross, Chief Executive
Officer

E-Mail: jack@synergychc.com

with copies to:

Nelson Mullins Riley & Scarborough
LLP

301 Hillsborough Street, Suite 1400

Raleigh, NC 27603

Attention: David Mannheim, Esq.

E-Mail: david.mannheim@nelsonmullins.com

or in each case to such other address as the person
to be notified may have requested in writing. Any party to this Agreement may change such address for notices by sending to the parties
to this Agreement written notice of a new address for such purpose.

11. Persons Entitled
to Benefit of Agreement. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective
successors and assigns and the controlling persons, officers and directors referred to in Section 7. Nothing in this Agreement is intended
or shall be construed to give to any other person, firm or corporation any legal or equitable remedy or claim under or in respect of this
Agreement or any provision herein contained. The term “successors and assigns” as herein used shall not include any purchaser,
as such purchaser, of any of the Shares from the Underwriters. Neither party may assign its rights or delegate its obligations under this
Agreement without the prior written consent of the other party.

12. Absence of Fiduciary
Relationship. The Company acknowledges and agrees that: (a) the Underwriters have been retained solely to act as underwriter in
connection with the sale of the Shares and that no fiduciary, advisory or agency relationship between the Company and the Underwriters
has been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether the Underwriters have advised
or are advising the Company on other matters; (b) the price and other terms of the Shares set forth in this Agreement were established
by the Company following discussions and arms-length negotiations with the Underwriters and the Company is capable of evaluating and understanding
and understands and accepts the terms, risks and conditions of the transactions contemplated by this Agreement; (c) it has been advised
that the Underwriters and its affiliates are engaged in a broad range of transactions that may involve interests that differ from those
of the Company and that no Underwriter has any obligation to disclose such interest and transactions to the Company by virtue of any fiduciary,
advisory or agency relationship; and (d) it has been advised that the Underwriters are acting, in respect of the transactions contemplated
by this Agreement, solely for the benefit of the Underwriters, and not on behalf of the Company.

13. Amendments and Waivers.
No supplement, modification or waiver of this Agreement shall be binding unless executed in writing by the party to be bound thereby.
The failure of a party to exercise any right or remedy shall not be deemed or constitute a waiver of such right or remedy in the future.
No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (regardless
of whether similar), nor shall any such waiver be deemed or constitute a continuing waiver unless otherwise expressly provided.

14. Partial Unenforceability.
The invalidity or unenforceability of any section, paragraph, clause or provision of this Agreement shall not affect the validity or enforceability
of any other section, paragraph, clause or provision.

15. Governing Law; Submission
to Jurisdiction. This Agreement shall be governed by and construed in accordance with the law of the State of New York. The Company
hereby irrevocably (a) submits to the jurisdiction of the Supreme Court of the State of New York or the United States District Court for
the Southern District of New York, in each case sitting the City and County of New York, for the purpose of any suit, action, or other
proceeding arising out of this Agreement or any of the agreements or transactions contemplated by this Agreement, the Registration Statement,
the Time of Sale Disclosure Package, any Prospectus and the Final Prospectus (each a “Proceeding”), (b) agrees that
all claims in respect of any Proceeding may be heard and determined in any such court, (c) waives, to the fullest extent permitted by
law, any immunity from jurisdiction of any such court or from any legal process therein, (d) agrees not to commence any Proceeding other
than in such courts, and (e) waives, to the fullest extent permitted by law, any claim that such Proceeding is brought in an inconvenient
forum.

16. WAIVER OF TRAIL BY
JURY. THE COMPANY HEREBY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM BASED UPON, ARISING OUT OF OR IN CONNECTION
WITH THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, THE REGISTRATION STATEMENT, THE TIME OF SALE DISCLOSURE PACKAGE,
ANY PROSPECTUS AND THE FINAL PROSPECTUS.

17. Counterparts.
This Agreement may be executed and delivered (including by facsimile transmission or electronic mail) in one or more counterparts and,
if executed in more than one counterpart, the executed counterparts shall each be deemed to be an original and all such counterparts shall
together constitute one and the same instrument.

[Signature page follows]

If the foregoing correctly
sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided below for that purpose,
whereupon this letter shall constitute a binding agreement between us.

Very truly yours,

SYNERGY CHC CORP.

Name:

Title:

Confirmed as of the date first above written